A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant Therapy Following Surgery and Radiation of High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC)

Grants and Contracts Details

StatusFinished
Effective start/end date10/7/1911/15/22

Funding

  • Merck Sharp & Dohme Corporation: $30,896.00